Co-expression of PD-L1 Antibodies Enhances the Anti-Tumor Efficacy of Chimeric Antigen Receptor T Cells

Journal of Cancer Research and Immuno-Oncology is a fast-developing open access journal in the field of cancer research. It focuses on becoming one of the best peer reviewed journal in the field of cancer research. Journal of Cancer Research and Immuno-Oncology covers a broad scope for the authors to make their valuable contributions in cancer biology, tumor, radiology, metastatis, cancer immunotherapy, oncology, radiation therapy etc

This Journal provides a unique forum dedicated to scientists to express their research articles, review articles, case reports and short communications on any array of latest cancer research and Immuno-Oncology. The Journal of Cancer Research and Immuno-Oncology is a Peer Reviewed Open Access Journal supported by universally prominent Editorial Board members. Abstracts and full texts of all articles published by Journal of Cancer Research and Immuno-Oncology are freely accessible to everyone.

Chimeric antigen receptor T (CAR-T) cell therapy against solid tumors has shown limited success in clinical trials. Solid tumors with highly immunosuppressive tumor microenvironment limit the anti-tumor efficacy of CAR-T cell therapy. Herein we generated a novel vector that co-express human mesothelin (MSLN)-targeted CAR and secretory human anti-programmed death ligand 1 (PD-L1) antibodies.

The anti-PD-L1 antibodies secreted from the transduced T cells were able to block the interaction of PD-1/PD-L1 to overcome PD-L1-mediated immune suppression. The CAR-T cells targeting mesothelin and secreting PD-L1 antibodies enhanced cytolytic activity against MSLN+PD-L1+ tumor cells and increased the production of cytokines IL-2, TNFα, and IFNγ.

The CAR-T cells targeting MSLN and secreting PD-L1 antibodies had enhanced anti-tumor efficacy when compared with the MSLN-targeted CAR-T cells in xenograft mouse models of mesothelioma, pancreatic and ovarian cancers. The results of this study demonstrated that the co-expression of PD-L1 antibody enhances the anti-tumor efficacy of CAR-T cell therapy against solid tumors.

The journal is using Editorial Manager System for quality in review process. Editorial Manager is an online manuscript submission, review and tracking system. Review processing is performed by the editorial board members of Journal of Cancer Research and Immuno-Oncology or outside experts; approval of at least two independent reviewers followed by the editor is required for acceptance of any citable manuscript.

Interested can submit their manuscript through online portal

Submit manuscript at https://www.longdom.org/submissions/cancer-research-immuno-oncology.htmll or send as an e-mail attachment to the Editorial Office at cancerresearch@clinicalres.org

Media contact:

Maegan Smith

Managing Editor

Journal of Cancer Research and Immuno-Oncology

Mail ID: cancerresearch@clinicalres.org       

WhatsApp no: + 1-504-608-2390